Ensemble Awarded Three Therapeutic Discovery Project Grants Totaling $744,000

-- Grants Support Development of Innovative Therapies for the Treatment of Rheumatoid Arthritis and Cancer --

CAMBRIDGE, MA – November 2, 2010 – Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecules therapeutics with the power of biologics, announced today that it has been awarded three grants totaling $744,000 under the IRS Qualifying Therapeutic Discovery Project (QTDP). The grants were awarded to Ensemble to help support further development of the Company’s oral macrocycle drug candidates for the treatment of rheumatoid arthritis (RA) and other inflammatory diseases as well as novel oncology treatments and diagnostics for predicting drug resistant breast cancer.

"We are pleased to see that the broad potential of our novel macrocycle drug discovery platform has been recognized through the award of these grants," said Michael D. Taylor, Ph.D., President and Chief Executive Officer of Ensemble Therapeutics. "These funds will help support the development of innovative drug candidates for the treatment of RA and cancer, as well as personalized medical diagnostics to predict drug resistant breast cancer."

The Qualifying Therapeutic Discovery Project (QTDP) is provided under new section 48D of the Internal Revenue Code (IRC). The QTDP grant is targeted to therapeutic discovery projects that show a reasonable potential to result in new therapies to treat areas of unmet medical need or prevent, detect or treat chronic or acute diseases and conditions, reduce the long-term growth of health care costs in the United States, or significantly advance the goal of curing cancer within 30 years.

About Ensemblins

Ensemblins™ are a new class of synthetic macrocycles developed by Ensemble using its proprietary chemistry platforms, including DNA-Programmed Chemistry™. Macrocyclic rings are found in many natural product-based drugs and bestow favorable pharmaceutical properties and powerful protein surface binding properties upon such drugs. Thus, macrocycles are uniquely suited to address many protein targets that cannot be modulated effectively by traditional small molecule pharmaceutical compounds. Macrocycles have been challenging to synthesize in large numbers and this has constrained their wider use in the industry. Ensemble has produced larger collections of macrocyclic drug candidates than any previously synthesized in the pharmaceutical industry.

About Ensemble Therapeutics
Based in Cambridge, MA, Ensemble Therapeutics is deploying its proprietary chemistry platforms to develop a novel class of therapeutics known as “Ensemblins”. Ensemble is the exclusive worldwide licensee from Harvard University of its patents covering DNA-Programmed Chemistry.

Ensemble is pursuing a proprietary drug pipeline and also collaborations with pharmaceutical partners. Ensemble has two drug discovery alliances with Bristol-Myers Squibb (April 2009) and Pfizer (January 2010). Ensemble’s lead proprietary programs are in the inflammatory disease field. For more information, visit: www.ensembletx.com.

Media Contact:
Gina Nugent
The Yates Network
617-460-3579